Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006

Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.

Authors

D E Furst¹, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, M H Weisman

Affiliation

¹ David Geffen School of Medicine, UCLA - RM 32-59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA. [email protected].

No abstract available

Publication types

Consensus Development Conference

MeSH terms

Abatacept
Antirheumatic Agents / adverse effects
Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / drug therapy
Arthritis, Rheumatoid / drug therapy
Humans
Immunoconjugates / adverse effects
Immunoconjugates / therapeutic use
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use*
Interleukin 1 Receptor Antagonist Protein / adverse effects
Interleukin 1 Receptor Antagonist Protein / therapeutic use
Rheumatic Diseases / drug therapy*
Spondylitis, Ankylosing / drug therapy
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Antirheumatic Agents
Immunoconjugates
Immunologic Factors
Interleukin 1 Receptor Antagonist Protein
Tumor Necrosis Factor-alpha
Abatacept